Johns Hopkins ABX Guide
COVID-19 Convalescent Plasma
INDICATIONS
FDA
FDA
- Previously available under Emergency Use Authorization (EUA, 12/28/21).
- FDA approved (page has link to product insert) high-titer COVID convalescent plasma in December 2024.
- Approved for treatment of COVID-19 in patients with immunocompromise-immunosuppressive disease/process or receiving immunosuppressive treatments at risk of severe disease progression in either the inpatient or outpatient settings.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: September 17, 2025
Citation
Dzintars, Kathryn . "COVID-19 Convalescent Plasma." Johns Hopkins ABX Guide, The Johns Hopkins University, 2025. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540631/all/COVID_19_Convalescent_Plasma.
Dzintars K. COVID-19 Convalescent Plasma. Johns Hopkins ABX Guide. The Johns Hopkins University; 2025. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540631/all/COVID_19_Convalescent_Plasma. Accessed October 5, 2025.
Dzintars, K. (2025). COVID-19 Convalescent Plasma. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540631/all/COVID_19_Convalescent_Plasma
Dzintars K. COVID-19 Convalescent Plasma [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2025. [cited 2025 October 05]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540631/all/COVID_19_Convalescent_Plasma.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - COVID-19 Convalescent Plasma
ID - 540631
A1 - Dzintars,Kathryn ,Pharm.D., BCPS
Y1 - 2025/09/17/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540631/all/COVID_19_Convalescent_Plasma
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
